Company ProfilePremium

BIOCERES CROP SOLU

Company Profile Analysis

Ticker: BIOX

ESOMAR 23 Corporate BadgeISO Certifications Badge
BIOCERES CROP SOLU - Company showcase

Year Founded & Workforce

2001

983 Employees

BIOCERES CROP SOLU logo

BIOCERES CROP SOLU Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BIOCERES CROP SOLU Overview

Bioceres Crop Solutions is an Argentine-rooted agricultural inputs and biotechnology company. It sells biologicals (inoculants, bio-protection seed treatments), adjuvants, micro-beaded fertilizers and third-party crop protection products, mainly through its 80%-owned subsidiary Rizobacter. It also holds licensed rights to the HB4® drought-tolerance trait for wheat and soybean. Between 2019 and 2024 the company used SPAC capital, the 2022 all-stock Marrone Bio merger and secured note financing to build what it called a "regenerative" crop-productivity platform. Revenue peaked at US$464.8M in FY2024. Since then the company has gone through an Argentine demand shock, a covenant breach, loss of control of its parent group, and the foreclosure of its U.S./European biologicals arm (Pro Farm). It also carries a going-concern qualification and a Nasdaq bid-price deficiency. Today BIOX is a sub-US$30M market-cap, highly levered (net financial debt US$213.6M), Argentina-centric inputs business. It is executing a cost-led turnaround while litigating with its noteholders.


What the company does

Bioceres develops, manufactures and sells crop-productivity inputs for row-crop agriculture (soybean, wheat, corn and others). Its continuing operations, after the PFG foreclosure, are concentrated in Argentina through Rizobacter Argentina S.A. (Pergamino). Rizobacter makes and sells three main things:

Inoculants: biological nitrogen-fixation products for legumes, plus related biological seed treatments.

Adjuvants: spray additives that improve the performance of agrochemicals.

Micro-beaded / micro-granulated fertilizers: produced at the Synertech Industrias joint-venture plant with De Sangosse.

Rizobacter also distributes third-party crop protection products. The Seed and Integrated Products segment, run historically through Bioceres Semillas, covered HB4 wheat and soybean seed sales, grain integration programs and "seed treatment packs." After a two-year reconfiguration it is now moving to an asset-light HB4 trait-licensing model (Form 20-F FY2025; FY2026 earnings release).

Company's own description (latest filings)

The FY2026 earnings release (September 14, 2026) describes the company as a leader in the development and commercialization of productivity solutions that regenerate agricultural ecosystems and make crops more resilient to climate change. It adds that its solutions create economic incentives for farmers to adopt environmentally friendlier practices. It cites a biotech platform with patented technologies for seeds and microbial inputs, plus next-generation Crop Nutrition and Protection solutions (paraphrased from the "About" boilerplate).

Business and revenue model

Revenue typeDescriptionIndicative weight (FY2026, continuing)
Proprietary product salesAdjuvants, inoculants, micro-beaded fertilizers, biological seed treatments sold to distributors, cooperatives and growersMajority of revenue. Precise split n/d.
Third-party product resaleThird-party crop protection products sold mainly in ArgentinaDeclining. Cited as a driver of lower Crop Protection revenue in FY2026.
Seed and grain integrationHB4 seed and grain programsBeing wound down. Seeds/HB4 caused about half of the FY2026 revenue decline.
Licensing / royaltiesHB4 trait licensing to third-party seed companies; Syngenta agreement for biological seed treatmentsGrowing in strategic importance. Syngenta contribution fell in FY2026.
Strategic up-front paymentsSyngenta up-front payment recognized over time (US$33M recognized in FY2023, about US$17M in FY2024, per FY2024 earnings call)Lumpy; it inflated FY2023–FY2024 Crop Nutrition margins

Subscription or SaaS revenue is n/d; the company has no material subscription model.

Value-chain position

Bioceres sits between technology discovery (CONICET/UNL-origin HB4 science; microbial strain libraries) and the farm gate. It combines its own manufacturing (Pergamino plants; Synertech JV) with distribution through Argentine agro-retail channels and international subsidiaries and distributors. Its key advantages are formulation know-how and channel reach in Argentina. Its key weaknesses are limited scale outside Argentina after losing Pro Farm, and dependence on Argentine farmer credit.

Customers and end-markets

Customer types: Agro-input distributors and retailers, cooperatives, large growers, seed companies (HB4 licensees and seed-treatment packs) and multinational partners (Syngenta).

End-markets: Soybean, wheat, corn and other row crops in Argentina (dominant), Brazil, the rest of Latin America, North America (heavily reduced after PFG) and EMEA.

Independent characterization

BIOX is now a distressed, single-country-dependent specialty-inputs company with a residual biotech option (HB4). Its core franchises are still profitable at the gross level: FY2026 continuing gross margin was 34.8% and 1H FY2026 consolidated gross margin was about 40% (CEO letter, March 2026). Equity value, however, is dominated by the capital structure. Secured notes carry 15–19% coupons, and their acceleration is disputed. Total financial debt of US$225.9M sits against FY2026 Adjusted EBITDA of US$25.5M. The investment case has shifted from "growth biotech" to "restructuring and recovery."

Strategy

Stated strategy themes (latest filings and letters, paraphrased)

  1. Focus on core capabilities. Concentrate on the continuing Argentine-anchored business and its "core technology platforms." The March 2026 CEO letter says continuing operations are centered on Argentina.

  2. Cost and operating discipline. Lower the fixed and variable cost base. FY2026 SG&A fell US$22.5M (−24%).

  3. Portfolio and channel rationalization. After an external strategic assessment completed in 2026, management plans to rationalize the portfolio and go-to-market channels, revisit commercial policies and strategic relationships, and tie R&D (which the company calls "R&D&R") to defined financial objectives (FY2026 release).

  4. Asset-light seeds. Complete the shift from own-channel HB4 seed sales to trait licensing (20-F FY2025; FY2026 release).

  5. Capital structure. Resolve the Pro Farm and noteholder situation through negotiation or litigation and "develop a sustainable capital structure" (CEO letter, March 2026). Continue liability management at Rizobacter (bank reprofiling) and a voluntary maturity extension on Argentine local bonds (obligaciones negociables).

  6. Three-year plan. The board directed management to build a comprehensive three-year financial plan for the business excluding Pro Farm, focused on profitability and cash flow (CEO letter, March 2026). The plan itself is not public.

Initiatives register (last 24 months)

DateInitiativeTypeDetail / targetStatus
FY2025Seed business reconfiguration (HB4 licensing)Business model transitionStop own-brand HB4 seed salesSubstantially completed (FY2026 release)
May 2025HB4 wheat license made exclusive worldwideIP / licensingAmendment to the March 2022 licenseEffective, but terminable after the June 2025 change of control
Jun 2025Note amendment and board refreshLiability managementCovenant reset to 5.0x; maturity extended to Aug 2027Superseded by the acceleration dispute
FY2026Cost reduction programCostOperating expenses −20% (US$103.2M to US$82.3M)Achieved
FY2026Rizobacter bank debt reprofilingLiability managementAgreements covering "a substantial portion" of bank maturitiesLargely done (3Q26 release)
FY2026Voluntary extension of Argentine local bondsLiability managementTerms n/dLaunched
FY2026External strategic assessment of continuing operationsStrategyRoadmap for portfolio, channels, R&DConcluded (FY2026 release)
FY2026Inventory normalizationWorking capitalInventories US$87.6M to US$46.1M; US$4.0M non-recurring obsolescence charge in 4Q26Ongoing
Sep 2026Nasdaq compliance planListingNotified intent to cure, possibly by reverse split; deadline March 15, 2027Pending
2,026Potential sale of non-strategic assetsPortfolioReported by Forbes ArgentinaUnconfirmed

Guidance and medium-term targets

No quantitative guidance has been provided for FY2027. Management lists qualitative priorities: cash generation, cost and working-capital discipline, and addressing the capital structure. On the 1Q26 call, management said it had operated "well above the gross margin limit" it set for itself, but did not specify the threshold in retrieved text.

Historical targets were missed. The HB4 wheat incremental EBITDA target of US$15–20M for FY2024 (set in FY2022) is no longer relevant after the licensing pivot. The ambition to grow FY2025 EBITDA above FY2024's US$81M was missed: actual FY2025 Adjusted EBITDA was US$28.3M.

ESG and sustainability commitments

The IR site lists a Sustainability Report, Scope 1 & 2 emissions disclosure, Product Environmental Assessments and CSR pages. Quantitative targets are n/d in retrieved sources.

Products & Services

Bioceres does not publish a full SKU-level catalog in its filings. The entries below are drawn from filings, earnings materials and press coverage. Pricing models are not disclosed, beyond the general model of distributor sales plus licensing royalties.

Crop Protection

Product lineDescription / capabilityTarget customerStatus / yearNotes
Adjuvants (Rizobacter)Spray additives that improve agrochemical efficacy, deposition and drift controlDistributors and growers in Argentina, Brazil, other LatAmMature; Brazil adjuvant sales "almost doubling" in 4Q FY2025 per CEOAdjuvants improved gross profit and margin in 4Q26 despite lower volumes in Brazil
RizodermaBiological (Trichoderma-based) seed treatment and bio-fungicideSoybean and wheat growersCommercialNamed in the 20-F risk factors
Bio-protection seed treatments (ex-PFG, U.S.)Biocontrol seed treatments that drove U.S. growth in FY2024–FY2025U.S. row-crop seed companies and growersLost with the PFG foreclosure (Jan 2026)Discontinued operations
Third-party crop protectionResale of generic and branded agrochemicalsArgentine distributorsDeliberately de-emphasizedFaced price competition; lower profitability in 4Q26
RinotecProduct whose regulatory approval was cited as an FY2025 milestone (Quartr event summary)—Approved FY2025Specifications n/d

Seed and Integrated Products

Product lineDescription / capabilityTarget customerStatus / yearNotes
HB4® wheatDrought-tolerant GM wheat built on a sunflower HaHB4 transcription-factor gene licensed from Bioceres GroupWheat seed companies (licensees) and growersArgentina approval 2020/2022; Brazil cultivation approval 2023; U.S. clearance cited FY2024Moving from own-channel seed sales to licensing (20-F FY2025); license terminable after the June 2025 change of control
HB4® soybeanDrought-tolerant GM soybeanSoybean seed companies and growersApproved across all soybean-producing countries in the Americas after the Uruguay/Bolivia approvals (late 2024)Licensing model
Seed treatment packsIntegrated packs of biological and chemical seed treatments sold alongside seedSeed companies and growersGrowing; higher gross profit in 4Q26A bright spot in a shrinking segment
Grain integration programs (HB4)Identity-preserved grain programsMillers and exportersBeing wound downLow margin; deliberately reduced

Crop Nutrition

Product lineDescription / capabilityTarget customerStatus / yearNotes
InoculantsRhizobia-based biological nitrogen fixation for soybean and other legumes. Rizobacter has claimed leadership in global soybean inoculant market share (Infocampo).Growers and distributors worldwideMatureFY2026 obsolescence adjustment on inoculants; lower contribution from the Syngenta agreement
Biological seed treatments supplied to SyngentaRizobacter-originated biological seed treatments distributed exclusively by Syngenta outside ArgentinaSyngenta (global distribution)Commercial since about FY2023Up-front payment recognized: US$33M in FY2023, about US$17M in FY2024
Micro-beaded / micro-granulated fertilizersStarter fertilizers produced by Synertech (Pergamino), with three lines marketed in Argentina and LatAmCorn and soybean growersPlant operating since 2016Main FY2026 growth driver (+36% in 4Q26); pricing pressure in 1Q26
BiostimulantsPlant biostimulants; strong European sales noted in FY2024 (partly PFG-linked)GrowersCommercialEuropean biostimulant exposure largely lost with PFG
UHC nitrogen-fixation technologyPatented biological nitrogen-fixation platformFuture product pipelinePatent obtained FY2024Commercial status n/d

Former Pro Farm Group portfolio (discontinued, January 2026)

The former Marrone Bio portfolio was headquartered in the U.S. with European operations. It included the bio-fungicide Regalia, the bio-insecticide Grandevo, the bio-insecticide/nematicide lines Venerate and Majestene, and the Stargus bio-fungicide. These brands left the group with the foreclosure. The company disputes the foreclosure in the New York litigation, so any future recovery or transition arrangement could change this status.

Financial Narrative

Income statement

Sources: FY2022 release (Sept 8, 2022): Adjusted EBITDA US$51.5M; FY2021 Adjusted EBITDA US$48.3M; Baseline Adjusted EBITDA US$61.9M. FY2023 release (Sept 11, 2023). FY2024 release (Sept 9, 2024), plus World-Grain/Cultivar for the FY2023 operating profit of US$54.2M and net income of US$20.2M. FY2025 release (Sept 9, 2025). FY2026 release (Sept 14, 2026).

FY2024 net income was later recast to US$7.3M in the FY2025 release, against US$6.2M originally. FY2025 total comprehensive loss was US$59.6M; FY2026 total comprehensive loss was US$231.4M.

FY2026 continuing EPS of −0.74 is derived as the parent-attributable continuing loss of US$46.9M divided by 63.6M shares. Including the discontinued loss, the derived EPS is about −3.56; the aggregator shows TTM EPS of −3.90.

Internal inconsistency flag. The FY2026 income statement shows a continuing net loss of US$54.4M. The attribution table below it sums to US$50.4M (parent US$46.9M plus NCI US$3.5M). The US$4.0M gap is unexplained in the release; await the FY2026 20-F.

Margins (%)

All margins are computed from reported figures. FY2025 continuing margins use the recast US$289.4M base.

Revenue CAGR. FY2023 to FY2026 (US$419.8M to US$238.3M) is −17.2% a year. This mixes bases: about US$46M of the decline is the PFG deconsolidation, so the organic decline is somewhat smaller. On a continuing basis, FY2025 to FY2026 was −17.7%.

Quarterly profile, FY2026

1Q26 was reported before the PFG reclassification. 2Q26 standalone metrics are n/d in retrieved sources; 2Q26 carried the US$179M non-cash impairment.

Balance sheet

FY2022–FY2024 balance sheet data are n/d in retrieved primary sources.

FY2026 current assets include US$44.4M of "assets subject to foreclosure," and current liabilities include US$29.4M of "liabilities subject to foreclosure." These are residual PFG items. 1Q26 total financial debt was US$242.5M (1Q26 call). The 3Q26 net financial debt of US$212.9M was described as stable versus 2Q26.

Cash flow

FY2025 operating cash flow of US$53.0M was +27% YoY (FY2025 release), which implies FY2024 of about US$41.7M.

FY2026 operating cash flow, capex and FCF are n/d in the earnings release. Management emphasized working-capital release: receivables fell from US$165.9M to US$98.2M and inventories from US$87.6M to US$46.1M. Part of that reduction is the PFG reclassification.

Capex history is n/d. Buybacks: a share repurchase program existed (20-F risk factor references it), but FY2025–FY2026 amounts are n/d. No material repurchases are likely given the liquidity position.

Ratios (computed; FY2025 continuing-basis P&L where applicable)

ROE and ROA for FY2025 need FY2024 balance sheet data, which is n/d. ROIC is n/m: operating income is negative and the invested-capital base is distorted by the foreclosure. The cash conversion cycle is n/d because COGS-based payables and inventory days would be distorted by the PFG reclassification.

On a simple FY2026 basis: receivables of US$98.2M against continuing revenue of US$238.3M is about 150 days; inventory of US$46.1M against COGS of US$155.4M is about 108 days; payables of US$57.6M against COGS is about 135 days. That gives an indicative cycle of roughly 120 days, which is high for the sector and typical of Argentine credit terms.

Commentary on trends, inflections and drivers

FY2022–FY2024: growth phase. Revenue rose from about US$336M to US$464.8M, powered by inoculants, adjuvants, the Marrone merger and HB4 launches. Adjusted EBITDA plateaued at about US$81M in both FY2023 and FY2024. Earnings quality was weaker than the headline: the Syngenta up-front accrual contributed US$33M in FY2023 and about US$17M in FY2024, flattering Crop Nutrition. Net income fell from US$20.2M to US$6.2M as financial costs and amortization rose.

FY2025: break. Revenue fell 28%. Argentine deregulation and disinflation removed farmers' incentive to stock inputs as a currency hedge, and micro-beaded fertilizer demand collapsed. 4Q FY2025 Adjusted EBITDA turned negative (−US$4.5M). The covenant breach (net leverage above 3.75x at March 31, 2025) forced the June 2025 note amendment, with costlier PIK-heavy terms and noteholder board seats. Operating cash flow of US$53.0M was a rare positive, achieved through receivables collection.

FY2026: cost reset amid restructuring. Continuing SG&A fell 24% to US$71.2M (variable −38%, fixed −19%), and total operating expenses fell 20% to US$82.3M. That limited the Adjusted EBITDA decline to −12% against an −18% revenue decline. Interest expense, however, jumped 53% to US$33.5M on PIK accrual and penalty economics, and the accelerated notes drove short-term classification. The PFG foreclosure produced a US$179.4M discontinued loss, which wiped out about 82% of total equity.

Inflection signals. 4Q26 revenue was flat YoY (+1%) and Adjusted EBITDA swung US$10.1M positive. Crop Nutrition grew 36% in the quarter, and adjuvants and seed-treatment packs improved gross profit. Against this, Rizobacter bank debt was reprofiled (long-term borrowings rose from US$38.2M to US$60.0M as short-term borrowings fell from US$119.7M to US$47.3M), which pushes near-term maturities out.

Key watch items. Interest coverage is below 1.0x and cash is only US$11.2M. Any outcome of the noteholder dispute that requires cash settlement of the US$118.6M notes would exceed available liquidity. That is the basis for the going-concern doubt the company itself discloses.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsPrincipal products/services

Crop Protection

Adjuvants, biologicals for pest and disease control, seed-protection products, third-party crop protection resale. Historically also PFG bio-protection (now discontinued).

Proprietary adjuvants (Argentina, Brazil); Rizoderma biological; third-party agrochemicals (Argentina)

Seed and Integrated Products

HB4 seed and grain programs, seed genetics, seed treatment packs

HB4 wheat and soybean (moving to licensing); integrated seed treatment packs

Crop Nutrition

Inoculants (biological nitrogen fixation), biostimulants, micro-beaded fertilizers, Syngenta agreement economics

Rizobacter inoculants; micro-beaded fertilizers (Synertech); biological seed treatments supplied to Syngenta

Revenue by Segment

Segment (Revenue, USD Mn)FY2025FY2026

Crop Protection

147.1123.7

Seed and Integrated Products

63.937.7

Crop Nutrition

78.577.0

Total Revenue

289.4238.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment (Revenue, USD Mn) Overview

Segment (Revenue, USD Mn)FY2025

Crop Protection

181.9

Crop Nutrition

89.5

Seed and Integrated Products (derived as total minus other segments)

63.9

Total Revenue

335.3

Revenue by Segment — Crop Protection

Segment (Gross profit, USD Mn)FY2025FY2026

Crop Protection

49.941.7

Seed and Integrated Products

19.117.4

Crop Nutrition

36.023.7

Total Gross Profit

105.082.9

Revenue by Segment (%)

Segment (Gross margin, %)FY2025FY2026

Crop Protection

33.933.7

Seed and Integrated Products

29.946.2

Crop Nutrition

45.930.8

Total

36.334.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue

SegmentFY2026 revenue YoY %FY2026 % of revenueFY2026 gross profit YoY %

Crop Protection

−1651.9−16

Seed and Integrated Products

−4115.8−9

Crop Nutrition

−232.3−34

Total

−18100.0−21

Segment (USD Mn) Overview

Segment (USD Mn)1Q26 (reported, incl. PFG)3Q26 (continuing)4Q26 (continuing)

Crop Protection

39.924.627.7

Seed and Integrated Products

12.63.24.8

Crop Nutrition

25.111.623.5

Total

77.539.455.9

Group Entities

EntityRoleOwnership

Bioceres Crop Solutions Corp. (Cayman)

Listed holding company

Public

RASA Holding

Holds the Rizobacter stake

100% (indirect)

Rizobacter Argentina S.A.

Core operating company (Pergamino): inoculants, adjuvants, fertilizers

80% via RASA Holding. 29% of BIOX's held shares are subject to a judicial injunction, and a contingent purchase price of US$17.3M is deemed likely payable (20-F FY2025).

Bioceres Semillas

Seeds / HB4 integrated programs

Subsidiary (details n/d)

BCS Holding Inc.

Party to the HB4 license

Subsidiary

Synertech Industrias S.A.

Micro-beaded fertilizer manufacturing

50/50 JV, Rizobacter / De Sangosse

Pro Farm Group, Inc. and subsidiaries (U.S., Brazil, Estonia/Finland, Russia)

Former Marrone Bio biologicals

Foreclosed January 2026; disputed; classified as discontinued

Income Statement and Per-Share Data

Metric (USD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue (as reported; FY2026 continuing)

—419.8464.8335.3238.3

Revenue — continuing-ops basis (ex-PFG)

———289.4238.3

Comparable revenue (non-IFRS, ex-IAS 29)

319.3————

Gross profit (as reported; FY2026 continuing)

——186.6131.782.9

Gross profit — continuing basis

———105.082.9

Operating income (as reported; FY2026 continuing)

—54.244.8-3.7-0.2

Operating income — continuing basis

———6.6-0.2

Adjusted EBITDA (company definition)

51.581.181.428.325.5

Adjusted EBITDA — continuing basis

———28.925.5

Loss before income tax — continuing

———-46.5-51.0

Net income — continuing operations

———-49.1-54.4

Net income — total (as reported)

—20.26.2-55.2-233.8

Loss from discontinued operations (PFG)

———-9.7-179.4

EPS basic, USD (aggregator for FY2022–FY2025; FY2026 derived continuing)

-0.170.300.07-0.88-0.74

Dividends per share, USD

00000

Margin Analysis (%)

Metric (%)FY2023FY2024FY2025FY2026

Gross margin

—40.139.334.8

Operating margin

12.99.6-1.1-0.1

Adjusted EBITDA margin

19.317.58.410.7

Net margin (total)

4.81.3-16.5-98.1

Net margin (continuing)

——-17.0-22.8

Financial Analysis

Metric (USD Mn)1Q263Q264Q26

Revenue

77.539.455.9

Gross profit

—12.712.7

Net income

-7.5-10.0-31.8

Adjusted EBITDA

13.6-0.60.6

Balance Sheet

Metric (USD Mn)FY2025FY2026

Total assets

763.6471.3

Cash and cash equivalents

32.711.2

Other short-term investments

2.01.0

Secured notes (current)

102.3118.6

Short-term borrowings

119.747.3

Long-term borrowings

38.260.0

Total financial debt

260.2225.9

Net financial debt

225.5213.6

Goodwill

112.236.1

Intangible assets

181.282.2

Total equity

295.264.1

Equity attributable to parent

265.439.1

Non-controlling interest

29.825.0

Total liabilities

468.4407.2

Working capital (current assets minus current liabilities)

-29.7-51.8

Trade receivables (current)

165.998.2

Inventories

87.646.1

Trade and other payables (current)

96.457.6

Cash Flow

Metric (USD Mn)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

——41.753.0—

Free cash flow (aggregator-derived)

——31.043.6—

Dividends paid

00000

Key Financials

Metric (USD Mn)FY2025FY2026

Interest expense

-21.9-33.5

Financial commissions

-3.2-4.5

Fair value, FX and other

-28.0-12.9

Total financial result

-53.1-50.9

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE (total net income / average equity), %

—-130.1

ROA (continuing net income / average assets), %

—-8.8

ROA (total net income / average assets), %

—-37.9

Current ratio, x

0.910.81

Debt / equity, x

0.883.52

Net debt / Adjusted EBITDA, x

7.88.4

Interest coverage (Adjusted EBITDA / interest expense), x

1.320.76

Asset turnover (revenue / average assets), x

—0.39

Revenue by Region

Region (Revenue, USD Mn)FY2023FY2024FY2025

Argentina

288.2346.8231.6

Brazil

23.724.217.7

Rest of Latin America

21.022.023.9

North America

30.427.430.1

EMEA

22.021.37.9

Rest of World

34.123.222.2

Total (contracts with customers)

419.4464.8333.3

Geographic Revenue

RegionFY2024 YoY %FY2025 YoY %FY2025 share %

Argentina

20.3-33.269.5

Brazil

2.0-26.95.3

Rest of Latin America

4.38.97.2

North America

-9.910.09.0

EMEA

-3.2-62.92.4

Rest of World

-31.9-4.46.7

Share Price & Returns

PeriodReturn %Start price USD

1 month

4.550.34

3 months

-12.250.41

Year to date (from Dec 31, 2025)

-72.611.31

1 year

-88.433.10

3 years

-96.9911.92

5 years

-97.3313.45

Since listing (March 15, 2019)

-92.684.90

Valuation Snapshot

MetricValueBasis

Market capitalization (USD Mn)

about 25

0.39 × 63.6M

Enterprise value (USD Mn)

about 264

Market cap plus net financial debt (213.6) plus NCI (25.0)

EV / Sales (x)

about 1.1

FY2026 continuing revenue

EV / Adjusted EBITDA (x)

about 10.3

FY2026 Adjusted EBITDA 25.5

P / Book (x)

about 0.6

Parent equity 39.1

P / E

n/m

Losses

Capital Instruments

InstrumentAmountTermsClassification

Secured Notes (convertible plus non-convertible)

118.6

Convertible: principal US$67.87M at amendment, 15% (5% cash / 10% PIK), maturity Aug 31, 2027. Non-convertible: US$29.08M, 19% (14% cash / 5% PIK), monthly amortization (20-F FY2025).

Current (accelerated; disputed). Balance does not reflect the US$15M credit bid.

Short-term borrowings

47.3

Mainly Argentine bank and working-capital debt

Current

Long-term borrowings

60.0

Includes reprofiled Rizobacter bank debt and local bonds

Non-current

Lease liabilities

10.9

Current 2.1; non-current 8.8

Mixed

Total financial debt (excluding leases)

225.9——

Analyst Conclusions

Management guidance

No numeric FY2027 guidance has been given. Management's stated priorities are improving performance and cash generation of continuing businesses, cost and working-capital discipline, and addressing capital structure and liquidity. The external strategic assessment has been concluded and a three-year plan is in development; neither has been published.

Consensus expectations

There is no reliable consensus. Coverage is minimal and targets are stale. Analysts should model scenarios rather than anchor on consensus.

Bull case

  1. Operational trough is behind. 4Q26 revenue was flat YoY and Adjusted EBITDA swung US$10.1M positive. With operating expenses now about US$82M a year, even a modest Argentine recovery could lift Adjusted EBITDA toward US$35–40M. That is an illustrative analyst scenario, not company guidance.

  2. Litigation leverage. If courts find the US$15M credit bid for about US$194M of assets commercially unreasonable, the note claim could be substantially reduced or offset, collapsing net debt.

  3. Optionality. HB4 royalties, Syngenta biologicals and possible asset sales offer non-linear upside against a roughly US$25M equity value.

Bear case

  1. Insolvency arithmetic. Interest of US$33.5M exceeds Adjusted EBITDA of US$25.5M, cash is US$11.2M, and US$165.9M of debt is current. Without a settlement or new money, a restructuring that wipes out equity is plausible.

  2. IP and partner fragility. The HB4 license is terminable and the licensor is bankrupt. The Syngenta contribution is falling and inoculants carry obsolescence charges. The "platform" may be worth less than its book value.

  3. Listing and dilution. A reverse split is likely, delisting is possible after March 2027, and a debt-for-equity outcome would heavily dilute current holders.

Catalysts and monitorables (next 12 months)

CatalystExpected timingWhat to watch
FY2026 Form 20-FBy October 31, 2026Auditor opinion and going-concern language, segment and geography data, compensation
New York litigation milestonesOngoingRulings on commercial reasonableness and counterclaims; settlement or transition agreement
1Q27 resultsAbout November 2026Argentine planting-season demand; Adjusted EBITDA run-rate
Reverse split / Nasdaq complianceBefore March 15, 2027Ratio, shareholder approval, hearing panel
Asset sales2026–2027Proceeds versus debt
HB4 license statusOngoingAny termination notice from the licensor or its bankruptcy trustee
Rizobacter local bond extensionOngoingParticipation rate
Argentine macro and creditFY2027 seasonFarmer credit, commodity prices, FX

Analyst verdict

Bioceres Crop Solutions is no longer the growth-biotech story it marketed between 2019 and 2024. It is a leveraged, Argentina-centric specialty-inputs operator whose equity is a residual claim behind a contested creditor position. The operating evidence is mixed but improving at the margin. Continuing gross margins held near 35–40%, SG&A was cut by about a quarter, and the fourth quarter of FY2026 delivered flat revenue and positive Adjusted EBITDA for the first time in a year. Crop Nutrition, especially micro-beaded fertilizers, adjuvants and seed-treatment packs, shows franchise durability in the core Argentine market.

The capital structure overwhelms that progress. Net financial debt of US$213.6M against US$25.5M of Adjusted EBITDA (about 8.4x) is unsustainable while interest expense exceeds EBITDA. US$118.6M of secured notes sit in default under a disputed acceleration, and the noteholders have already taken the Pro Farm platform for a US$15M credit bid. Equity attributable to shareholders has fallen to US$39.1M. The auditor-level going-concern doubt, the Nasdaq deficiency and the bankruptcy of the former parent, which is also the HB4 licensor, add layers of non-operating risk that ordinary fundamental analysis cannot price with confidence.

The outcome distribution is therefore bimodal. A favorable litigation result or negotiated settlement, combined with asset sales and an Argentine credit recovery, could re-rate an equity priced near US$25M against an enterprise generating about US$25–40M of EBITDA. A creditor-led restructuring, which current cash and coverage metrics make at least as likely, would leave little for existing shareholders. For most institutional mandates, BIOX is not investable as a fundamental long. It belongs, if anywhere, in special-situations or distressed books with legal expertise on New York UCC foreclosure law. The key near-term tells are the FY2026 20-F audit opinion, any settlement or court ruling in New York, and the 1Q27 Argentine selling-season print.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / appointmentBackground (disclosed)Compensation

Federico Trucco, PhD

CEO and Executive Director

Bioceres group since 2005; CEO since 2011 (about 15 years)

Bioceres LLC President since 2012; Bioceres S.A. board since 2014 (removed December 2025 per press); President of the Argentine Chamber of Biotechnology (2020)

Individual figures n/d (foreign private issuer, aggregate disclosure). Direct ownership about 0.6% (Simply Wall St).

Ezequiel Simmermacher

Chief Financial Officer

Effective January 5, 2026

Prior roles n/d in retrieved sources

—

Alejandro Villafañe

Principal Accounting Officer

Appointed during the CFO vacancy (2025)

——

José Roque

General Counsel

Spoke on the 3Q26 call (2026)

——

Maria Paula Savanti

Head of Investor Relations

Long-standing IR head

——

Enrique López Lecube

Former CFO

CFO since before the 2019 listing; stepped down in 2025

Left the board June 2025 and the CFO role August 2025

—

Board of Directors

DirectorRoleSinceBackground

Federico Trucco

Executive Director / CEO

2019

See above

Yogesh Mago

Non-executive Director

July 12, 2022 (ex-Marrone Bio board)

Co-founder and President of Operation Water Inc.; advisory board of Girl Rising; BS Finance and International Business, NYU

Duraiswami ("D") Narain

Non-executive Director

December 29, 2025

Ex-Vice Chairman, MD and CEO of Bayer CropScience Ltd (India), 2018–2023; Bayer global head of smallholder farming; non-executive director of RiceTec; founding partner of AgVaya; chairs the board of "AIG" (identified as Agriculture Investment Group, a major BIOX holder) and is a non-executive director of Elemental Altus. MBA Kellogg; Chartered Accountant (ICAI).

Second Q2 FY2026 non-executive appointee

Non-executive Director

Q2 FY2026

The CEO letter (March 2026) cites two new non-executive directors in 2Q FY2026; the second name was not confirmed in retrieved sources

Major Shareholders

HolderSharesStake %Source / date

Agriculture Investment Group (AIG)

about 9.1–9.8M

14.4–15.4

Simply Wall St (2026). Insider-type filings show a purchase of about 2.36M shares in October 2025 and sales in February 2026.

Ospraie Management, LLC

6,233,5909.82

Simply Wall St

Solel Partners LP

4,579,3647.21

Simply Wall St

Fourth Sail Capital LP

4,331,0966.82

Simply Wall St

Bioceres S.A. (in bankruptcy)

3,189,1615.02

Simply Wall St; holding down 66%

Long Focus Capital Management

829,7481.31

Simply Wall St

Mirae Asset Global Investments

751,5301.18

Simply Wall St

Marshall Wace LLP

595,4100.94

Simply Wall St

Jasper Lake Ventures One LLC / Noah Kolatch

397,000 held; 8,710,707 beneficial including convertible notes

12.13 (beneficial, as-converted)

Schedule 13D/A (2026) via StockTitan

Federico Trucco

about 0.37M (implied)

about 0.6

Simply Wall St

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs. BIOX

Crop Protection (adjuvants, chemicals)

Corteva Agriscience

Global leader in seeds and crop protection; scale and R&D far larger

Crop Protection

Bayer Crop Science

Global chemical and seed major; strong Argentine channel

Crop Protection

Syngenta Group

Partner in biologicals, competitor in chemicals

Crop Protection

BASF Agricultural Solutions

Chemicals, inoculants (legacy Becker Underwood)

Crop Protection / biologicals

UPL (including NPP natural plant protection)

Generics plus biosolutions; aggressive in LatAm

Crop Protection

FMC Corporation

Diamides and a biologicals push

Crop Protection (generics, Argentina)

Local and Chinese-sourced generic formulators

Price competition in third-party products

Crop Nutrition (inoculants)

Novonesis (ex-Novozymes/Chr. Hansen)

Global microbial leader

Crop Nutrition (inoculants)

Lallemand Plant Care; Indigo Ag; Pivot Bio (U.S. nitrogen)

Biological nitrogen alternatives

Crop Nutrition (Brazil biologicals)

Biotrop (Biobest); Koppert

Strong in Brazil biologicals

Seeds / traits

Grupo Don Mario (GDM), Bayer, Corteva, Syngenta seeds; wheat breeders

HB4 must ride on licensee germplasm

Distribution / LatAm inputs

Lavoro (Brazil)

Distribution peer, also distressed

Peer Comparison FY2026

CompanyFiscal yearRevenueYoY growth %EBITDA margin %R&D % of salesSource

Bioceres Crop Solutions

FY2026 (Jun)

238.3

−18 (continuing)

10.7 (Adjusted)

4.7

FY2026 release

Corteva

FY2025 (Dec)

17,401+3

22.1 (operating EBITDA US$3,848M)

n/d here

Corteva 10-K FY2025

FMC

FY2025

—————

UPL

FY2026 (Mar)

—————

Recent Developments

--

Company Snapshot

983

Employees

$22.7M

Market Cap

2001

Founded

Province of Santa Fe, Argentina

Headquarters

SWOT Analysis

Strengths

  • Resilient gross margins. FY2026 continuing gross margin was 34.8%, and 1H FY2026 consolidated gross margin was about 40% (FY2026 release; CEO letter).
  • Demonstrated cost agility. FY2026 SG&A fell 24% (US$22.5M) and operating expenses fell 20% (FY2026 release).
  • Crop Nutrition momentum. 4Q26 revenue +36% and gross profit +37%, led by micro-beaded fertilizers (FY2026 release).
  • Unique trait. HB4 soy is approved across all soybean-producing countries in the Americas (Cultivar, November 2024).
  • Blue-chip validation. The Syngenta global distribution agreement generated US$33M of up-front recognition in FY2023 (FY2024 call).
  • Proven cash generation in a downturn. FY2025 operating cash flow was US$53.0M, +27% (FY2025 release).

Weaknesses

  • Leverage. Net financial debt of US$213.6M is 8.4x FY2026 Adjusted EBITDA (computed).
  • Interest burden. Interest expense of US$33.5M exceeds Adjusted EBITDA of US$25.5M (FY2026 release).
  • Liquidity. Cash of US$11.2M at June 30, 2026, against US$165.9M of current debt including notes (FY2026 release).
  • Going-concern qualification in FY2025 and reiterated in FY2026 interim reporting (20-F FY2025; CEO letter).
  • Concentration. Argentina was 69.5% of FY2025 revenue (20-F FY2025).
  • Governance instability. Six director exits between June and December 2025, plus a CFO vacancy from August 2025 to January 2026.

Opportunities

  • Litigation upside. The company argues the US$15M credit bid for about US$194M of carrying value was commercially unreasonable, and its counterclaims could reduce or extinguish note claims (3Q26 call).
  • HB4 royalties. The asset-light licensing model could produce high-margin royalties; HB4 wheat royalties were cited at about 80% margins on the FY2023 call.
  • Argentine recovery. Improving macro conditions, cited by the CEO in March 2026, could restore input demand and distributor credit.
  • Brazil biologicals expansion through adjuvants and seed-treatment packs.
  • Asset sales of non-strategic assets to deleverage (Forbes Argentina, September 2026).
  • Debt reprofiling. Rizobacter's bank reprofiling has already lifted long-term borrowings to US$60.0M from US$38.2M.

Threats

  • Note claims. US$118.6M of disputed notes are classified as current; an adverse ruling could trigger insolvency (FY2026 release).
  • HB4 license termination following the June 2025 change of control at the licensor (20-F FY2025).
  • Licensor insolvency. Bioceres S.A. is in bankruptcy, which complicates IP and shareholder dynamics (Canal26, March 2026).
  • Delisting. The March 15, 2027 deadline is close, and the stock traded at about US$0.35–0.39 in August–September 2026.
  • Rizobacter stake risk. An injunction covers part of the 80% stake, and a US$17.3M contingent payment is deemed likely payable (20-F FY2025).
  • Pricing pressure in micro-beaded fertilizers and third-party crop protection in Argentina (1Q26 and FY2026 releases).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 16, 2025HB4 wheat license amended to worldwide exclusivityStrengthens IP position, but termination exposure follows a month later
Jun 2025Bioceres S.A. (former parent) defaults on part of its debtGroup-level distress begins
Jun 16, 2025Moolec acquires Bioceres Group; change of controlHB4 license becomes terminable; parent deconsolidates BIOX
Jun 18, 2025Secured note amendments waive the leverage breach; maturity extended to Aug 31, 2027; coupons raised (15% and 19%, partly PIK)Bought time at high cost
Jun 20–24, 2025Board overhaul: noteholder nominees Marinov, Kolatch and Crocco joinCreditor influence in governance
Aug 2025CFO López Lecube steps downLeadership gap
Aug 31, 2025Marinov resigns from the boardStart of noteholder-director exits
Sep 9, 2025FY2025 results: revenue −28%, net loss US$55.2M, operating cash flow US$53.0MCEO calls it an extremely challenging year
Sep 30 / Oct 10, 2025Kolatch and Crocco resignNoteholder–company relationship turns adversarial
Nov 10, 2025FY2025 20-F filed with going-concern doubt and no permanent CFOAudit-level red flag
Nov 2025Acceleration notice; noteholders sue in New YorkPuts the whole note balance in default
Nov 12, 20251Q26 results: revenue US$77.5M (−17%), Adjusted EBITDA US$13.6M (+61%)Margin and cost progress
Dec 2025NY court decision; foreclosure sale adjourned to January 2026Temporary reprieve
Dec 2025Trucco removed from the Bioceres S.A. board (press)Escalating Trucco–Sartori dispute
Dec 26–29, 2025Zang resigns; Narain joins the boardBoard refresh with ag-industry experience
Jan 5, 2026Simmermacher becomes CFOFinance leadership restored
Jan 2026Bioceres S.A. files for *concurso preventivo*Licensor and former parent insolvent
Jan 20, 2026PFG foreclosure auction; US$15M credit bid by the noteholder JVLoss of U.S./EU biologicals
Feb 2026Short interest reportedly up 71% (aggregator)Bearish positioning
Mar 4, 2026Bioceres S.A. declared bankrupt by a Rosario courtShareholder of record about 5%; HB4 licensor risk
Mar 16, 20262Q26 6-K: US$179M impairment; CEO letter; going concern reiteratedEquity largely erased
Mar 16, 2026Nasdaq bid-price deficiency letterListing risk
May 11, 20263Q26: revenue US$39.4M (−23%), Adjusted EBITDA −US$0.6M; inoculant obsolescence chargeTrough quarter
3Q26 callGeneral Counsel says the NY case remains in early stages; counterclaims assertedLitigation duration risk
2026Rizobacter bank debt reprofiling agreements; local bond extension launchedNear-term liquidity relief
Sep 14, 2026FY2026 results: 4Q26 revenue US$55.9M (+1%), Adjusted EBITDA +US$0.6M; FY2026 Adjusted EBITDA US$25.5MFirst stabilization signal
Sep 15–18, 2026Move to the Nasdaq Capital Market; compliance deadline extended to March 15, 2027Reverse split likely
Sep 2026Forbes Argentina reports the company is analyzing non-strategic asset salesPotential deleveraging

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue (as reported; FY2026 continuing) fell from USD 419.8 Mn in FY2023 to USD 238.3 Mn in FY2026.
BIOCERES CROP SOLU — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue (as reported; FY2026 continuing)—419.8464.8335.3238.3
Revenue — continuing-ops basis (ex-PFG)———289.4238.3
Comparable revenue (non-IFRS, ex-IAS 29)319.3————
Gross profit (as reported; FY2026 continuing)——186.6131.782.9
Gross profit — continuing basis———10582.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bioceres Crop Solutions, FY2026 earnings release (Form 6-K Ex. 99.1, Sept 14, 2026) (sec.gov)
  2. Bioceres Form 6-K, Nasdaq transfer and extension (Sept 2026) (sec.gov)
  3. Bioceres 3Q FY2026 release (May 11, 2026) (secure.businesswire.com)
  4. Bioceres 3Q FY2026 6-K exhibit (sec.gov)
  5. Bioceres 1Q FY2026 release (Nov 12, 2025) (sec.gov)
  6. 1Q FY2026 earnings call transcript (roic.ai) (roic.ai)
  7. CEO shareholder letter (Mar 16, 2026) (financialcontent.com)
  8. Nasdaq bid-price letter (6-K, Mar 16, 2026) (sec.gov)
  9. UCC foreclosure sale 6-K (Jan 2026) (sec.gov)
  10. Court decision 6-K (Dec 2025) (sec.gov)
  11. Acceleration notice 6-K (Nov 2025) (sec.gov)
  12. Form 20-F FY2025 (filed Nov 10, 2025) (sec.gov)
  13. FY2025 earnings release (Sept 9, 2025) (sec.gov)
  14. FY2025 earnings call transcript (roic.ai) (roic.ai)
  15. FY2024 earnings release (Sept 9, 2024) (businesswire.com)
  16. FY2024 earnings call transcript (roic.ai) (roic.ai)
  17. World-Grain, FY2024 coverage (world-grain.com)
  18. FY2023 earnings release (Sept 11, 2023) (businesswire.com)
  19. FY2022 earnings release (Sept 8, 2022) (businesswire.com)
  20. 1Q FY2025 release (Nov 11, 2024) (sec.gov)
  21. Revista Cultivar, 1Q FY2025 / HB4 soy approvals (revistacultivar.com.br)
  22. Board changes (June 20, 2025) (businesswire.com)
  23. CFO departure 6-K (Aug 2025) (sec.gov)
  24. CFO appointment and board changes (Dec 2025) (qnow.quantisnow.com)
  25. Moolec Science Form 6-K (2025) on BIOX deconsolidation and note amendment (sec.gov)
  26. Marrone Bio merger completion (July 12, 2022) (businesswire.com)
  27. BIOX board of directors page (investors.biocerescrops.com)
  28. World-Grain, "Bioceres discloses dire financial picture" (2026) (world-grain.com)
  29. Fertilizer Daily, FY2026 coverage (fertilizerdaily.com)
  30. Fertilizer Daily, 2Q26 impairment (fertilizerdaily.com)
  31. Motley Fool 3Q26 transcript (fool.com)
  32. Bloomberg Línea, Nasdaq extension (Sept 2026) (bloomberglinea.com)
  33. Forbes Argentina, FY2026 restructuring (forbesargentina.com)
  34. Canal26, Bioceres S.A. bankruptcy (Mar 4, 2026) (canal26.com)
  35. Bichos de Campo, Bioceres S.A. concurso (Jan 2026) (bichosdecampo.com)
  36. El Cronista, shareholder dispute (cronista.com)
  37. Schedule 13D (Bioceres Group, 2025) (sec.gov)
  38. Jasper Lake Schedule 13D/A (via StockTitan) (stocktitan.net)
  39. Simply Wall St ownership (BIOXD) (simplywall.st)
  40. Simply Wall St management (BIOXD) (simplywall.st)
  41. Motley Fool quote page (price history) (fool.com)
  42. roic.ai BIOX data (roic.ai)
  43. Macrotrends employee count (macrotrends.net)
  44. Revelio Labs workforce data (reveliolabs.com)
  45. Engormix, Rizobacter expansion (2022) (engormix.com)
  46. Mercado, Synertech JV (2016) (mercado.com.ar)
  47. Infocampo, Rizobacter investment (infocampo.com.ar)
  48. Bichos de Campo, Syngenta agreement (bichosdecampo.com)
  49. Corteva Form 10-K FY2025 (sec.gov)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.